Details

Autor(en) / Beteiligte

• Mouyen, Thomas
• Manigold, Thibaut
• Collet, Jean‐Philippe
• Durand, Eric
• Barbey, Christophe
• Lhermusier, Thibault
• Tchetche, Didier
• Chollet, Thomas
• Mulliez, Aurélien
• Motreff, Pascal
• Combaret, Nicolas
• Souteyrand, Géraud

Titel

Transcatheter aortic valve thrombosis: Data from a French multicenter cohort analysis

Ist Teil von

• Catheterization and cardiovascular interventions, 2021-08, Vol.98 (2), p.352-362

Ort / Verlag

Hoboken, USA: John Wiley & Sons, Inc

Erscheinungsjahr

2021

Link zum Volltext

Quelle

Wiley Online Library Journals Frontfile Complete

Beschreibungen/Notizen

• Objectives To evaluate the effectiveness of anticoagulant therapies in patients with clinical transcatheter heart valve (THV) thrombosis, to describe complications, and to assess their risk profile was the objectives. Background Little research has been conducted on clinical THV thrombosis. Methods Patients with clinical THV thrombosis were identified based on greater than 50% increased transvalvular gradient on transthoracic echocardiogram confirmed by 4‐dimensional computed tomography, transesophageal echocardiogram, or regression with anticoagulant therapy. A cohort free from thrombosis for more than 1,100 days postprocedure was used for comparison. Results Fifty‐four patients with clinical THV thrombosis were identified. Most subjects (98.1%) received anticoagulant therapy which was effective (≥50% reduction in transvalvular gradient or return to postprocedure value) in 96%. The rate of serious hemodynamic or embolic complications in the thrombosis population was 31.5%. A multivariate analysis of subjects with and without thrombosis indicated a significantly increased risk of thrombosis from preexisting thrombocytopenia (odds ratio [OR] 9.96), absence of predilatation (OR = 5.67), renal insufficiency (OR = 4.84), and >10 mmHg mean transvalvular gradient postprocedure (OR = 3.36). No recurrence of thrombosis was identified during on average 685 days follow‐up. Conclusions These data, from one of the largest cohorts with clinical THV thrombosis confirm anticoagulants appear effective. The rate of serious associated complications was high. The findings underline the importance of recognizing risk factors for thrombosis.